At CFO (Boardroom Media) we track over 1,000,000 startups and over 5,000,000 people who hold key positions in these companies. We use this directory of startups to highlight top employees, founders and board members we think deserve more appreciation than they are currently getting.
This list showcases the top New York based CFO’ operating in the Therapeutics space. If you think a CFO’ is missing from this list, feel free to contact our editor on [email protected].
The individuals on this list have been included because of exceptional performance in one of the following categories:
- Innovation – Operating as a key part in an extremely innovative business or startup.
- Growth – Operating as a key figure in the growth and upscale of a market leading business or startup.
- Management – Showing exceptional management skills.
- Societal impact – Putting their business on the map for their positive societal or environmental impact.
Our Data – We source our data from OSINT (open source intelligence) and public directories such as Crunchbase, SemRush and many more. The data from these sources should be treated with a degree of caution and verified yourself.
Brett Kaplan
Chief Financial Officer of Prevail Therapeutics
Brett Kaplan is our Chief Financial Officer. Prior to Prevail, he was Managing Director at Evercore, where he spent eight years concentrating on biopharma M&A and equity financings. Prior to Evercore, Brett was an Equity Research Analyst at Cowen, where he covered large cap pharmaceuticals. Earlier in his career, he held senior positions at Cubist and Lilly focused on corporate and business development. Brett holds an MBBCh and an MBA from the University of Witwatersrand in South Africa.
Follow Brett Kaplan:
About Prevail Therapeutics: Prevail Therapeutics is a biotechnology company focused on developing novel gene therapies for patients with Parkinson’s disease.
Adam Cutler
Chief Financial Officer of Molecular Templates
Adam Cutler has served as Molecular Templates’ Chief Financial Officer since November 2017.Prior to joining Molecular Templates, he was Senior Vice President of Corporate Affairs at Arbutus Biopharma from 2015-2017, where his responsibilities included investor relations, business development, and corporate finance. From 2012-2015, he was a Managing Director for The Trout Group and Trout Capital, where he executed financings and advised life science companies on investor relations, capital raising, and business development. From 2000-2011, he was a biotechnology equity research analyst at Credit Suisse, Canaccord Genuity, JMP Securities, and Bank of America Merrill Lynch. He also worked in healthcare consulting at The Frankel Group and Ernst & Young. He currently serves on the Board of Directors for Inmed Pharmaceuticals and Navidea Biopharmaceuticals. He received his B.A. in Economics from Brandeis University.
Follow Adam Cutler:
About Molecular Templates: Molecular Templates develops novel therapeutic compounds for cancer.
Jaime Bartushak
CFO of Citius Pharmaceuticals
Follow Jaime Bartushak:
About Citius Pharmaceuticals: Citius Pharmaceuticals is a specialty pharmaceutical company dedicated to the development and commercialization of therapeutic products.
Douglas Larson
Group Chief Financial Officer of Beyond Air
Douglas Larson is the Group Chief Financial Officer at Beyond Air.
Follow Douglas Larson:
About Beyond Air: Beyond Air is a biotechnology company focused on the development of drugs for the treatment of lung infections.
Melissa Epperly
Chief Financial Officer of Psioxus Therapeutics
Melissa Epperly is a senior finance executive with deep healthcare experience. Prior to joining PsiOxus, Melissa was CFO and Head of Business Development at R-Pharm US, a commercial-stage oncology pharmaceutical company based in Princeton, NJ. At R-Pharm US she led corporate and business development, leading the integration of the asset purchase of Ixempra ® (a metastatic breast cancer treatment) from Bristol-Myers Squibb. Previously, Melissa was a Director at Anchorage Capital Group, a credit-focused hedge fund, where she drove operational excellence in their portfolio companies to facilitate and enable exponential growth. Prior to that she was a Vice President at Goldman Sachs in equity research where she helped develop, build, and commercialize a novel, global equity research product for long-term investing, GS SUSTAIN, in the US and Europe. Before joining Goldman Sachs she was a management consultant with Bain & Company in New York and London, focused on international and US based pharmaceutical clients and private equity. She previously worked at Morgan Stanley in New York in healthcare investment banking and banking management, enabling pharmaceutical and biotech companies to accelerate growth through strategic MandA and capital raising. Melissa holds an MBA from Harvard Business School and BA in Biochemistry and Economics from the University of Virginia, where she graduated Phi Beta Kappa.
Follow Melissa Epperly:
About Psioxus Therapeutics: Psioxus Therapeutics is a cancer gene therapy company delivers medicines of value to patients with cancer.
William Harris
CFO of EnGeneIC
Follow William Harris:
About EnGeneIC: EnGeneIC develops and commercializes the treatment of cancer through the targeted delivery of therapeutic agents directly to cancer cells.
Lawrence A. Kenyon
Chief Financial Officer of Outlook Therapeutics
Lawrence A. Kenyon is the Chief Financial Officer of Outlook Therapeutics.
Follow Lawrence A. Kenyon:
About Outlook Therapeutics: Outlook Therapeutics is a biopharmaceutical company focused on developing and commercializing monoclonal antibody biosimilar therapeutics.